Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views

File Description SizeFormat 
90440 Maher_Pt Phys disconnect ms_revised submission_3MAY18_clean.docxAccepted version374.24 kBMicrosoft WordView/Open
Title: Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views
Authors: Maher, TM
Swigris, JJ
Kreuter, M
Wijsenbeek, M
Cassidy, N
Ireland, L
Axmann, J
Nathan, SD
Item Type: Journal Article
Abstract: BACKGROUND: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%. OBJECTIVE: To investigate the views of individuals with IPF and pulmonologists on the diagnosis and management of IPF to understand treatment patterns. METHODS: Interviews and/or online surveys were completed by patients and pulmonologists from Canada, France, Germany, Italy, Spain, and the UK. Responses from physicians were analyzed by time between diagnosis and treatment initiation in the majority of patients with IPF (group A, > 4 months; group B, ≤4 months). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant. RESULTS: The physicians in group A saw fewer patients, were less comfortable discussing the IPF prognosis with patients, and had less belief in the benefits of antifibrotic treatments than the physicians in group B. These physicians' attitudes contrasted with those of the patients, who wanted more information about the IPF prognosis and pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects. Differences between countries were found regarding physicians' comfort in discussing the prognosis at diagnosis and access to care. CONCLUSIONS: Several barriers to antifibrotic treatment, principally reflecting the differing views and values of patients and physicians, were identified in this study, suggesting a need for better patient-physician communication about pharmacological therapy for IPF.
Issue Date: 16-Aug-2018
Date of Acceptance: 5-Jun-2018
URI: http://hdl.handle.net/10044/1/61844
DOI: https://doi.org/10.1159/000490667
ISSN: 1423-0356
Publisher: Karger Publishers
Start Page: 514
End Page: 524
Journal / Book Title: Respiration
Volume: 96
Issue: 6
Copyright Statement: © 2018 S. Karger AG, Basel.
Keywords: Antifibrotic treatment
Barriers to treatment
Idiopathic pulmonary fibrosis
Patient-physician communication
Antifibrotic treatment
Barriers to treatment
Idiopathic pulmonary fibrosis
Patient-physician communication
1102 Cardiorespiratory Medicine and Haematology
Respiratory System
Publication Status: Published online
Conference Place: Switzerland
Online Publication Date: 2018-08-16
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons